Vaxcyte, Inc.
PCVX
$59.48
-$0.88-1.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.61% | 2.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.45% | 26.09% | |||
| Operating Income | 12.45% | -26.09% | |||
| Income Before Tax | 11.33% | -30.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.33% | -30.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.33% | -30.07% | |||
| EBIT | 12.45% | -26.09% | |||
| EBITDA | 12.58% | -28.53% | |||
| EPS Basic | 14.39% | -27.20% | |||
| Normalized Basic EPS | 14.39% | -27.19% | |||
| EPS Diluted | 14.39% | -27.20% | |||
| Normalized Diluted EPS | 14.39% | -27.19% | |||
| Average Basic Shares Outstanding | 3.58% | 2.25% | |||
| Average Diluted Shares Outstanding | 3.58% | 2.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||